Myositis Ossificans (Fibrodysplasia Ossificans Progressiva)

11/13/2023 - "Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva."
10/01/2022 - "Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial."
11/01/2023 - "Palovarotene is under development for the treatment of fibrodysplasia ossificans progressiva (FOP). "
01/01/2019 - "We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva."
01/01/2023 - "Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)."

11/01/2001 - "Familial fibrodysplasia ossificans progressiva: trial with etidronate disodium."
12/01/1994 - "We describe a child who was treated for 10 years with etidronate disodium for myositis ossificans. "
12/01/1994 - "Myositis ossificans progressiva: a 10-year follow-up on a patient treated with etidronate disodium."
07/01/1993 - "Etidronate was serendipitously found to abate calcification in a child with myositis ossificans progressiva. "
01/01/1993 - "A child with myositis ossificans progressiva was treated for 8 years with ethane-1-hydroxy-1,1-diphosphonate (EHDP) 30-40 mg/kg per day. "

06/01/2022 - "Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)."
01/01/2021 - "Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva."
01/01/2021 - "ActivinA Induced SMAD1/5 Signaling in an iPSC Derived EC Model of Fibrodysplasia Ossificans Progressiva (FOP) Can Be Rescued by the Drug Candidate Saracatinib."

05/01/1975 - "The diphosphonate, disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) has been shown in clinical studies to be effective against ectopic calcification particularly in myositis ossificans progressiva and in disorders of increased bone resorption such as Paget's diseases and some types of osteoporosis. "

03/01/2011 - "A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date."
03/01/2011 - "Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G > A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T > C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. "
01/01/2023 - "Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish."
06/01/2012 - "Fibrodysplasia ossificans progressiva (FOP) causes extensive heterotopic bone formation due to heterozygous mutations in the glycine-serine activation domain of ACVR1 (ALK2), a bone morphogenetic protein type I receptor. "
11/01/2009 - "Patients with classic fibrodysplasia ossificans progressiva, a disorder characterized by extensive extraskeletal endochondral bone formation, share a recurrent mutation (R206H) within the glycine/serine-rich domain of ACVR1/ALK2, a bone morphogenetic protein type I receptor. "

03/01/2011 - "A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date."
03/01/2011 - "Fibrodysplasia Ossificans Progressiva (FOP) is a rare, autosomal dominant condition, classically characterised by heterotopic ossification beginning in childhood and congenital great toe malformations; occurring in response to a c.617 G > A ACVR1 mutation in the functionally important glycine/serine-rich domain of exon 6. Here we describe a novel c.587 T > C mutation in the glycine/serine-rich domain of ACVR1, associated with delayed onset of heterotopic ossification and an exceptionally mild clinical course. "
06/01/2012 - "Fibrodysplasia ossificans progressiva (FOP) causes extensive heterotopic bone formation due to heterozygous mutations in the glycine-serine activation domain of ACVR1 (ALK2), a bone morphogenetic protein type I receptor. "
11/01/2009 - "Patients with classic fibrodysplasia ossificans progressiva, a disorder characterized by extensive extraskeletal endochondral bone formation, share a recurrent mutation (R206H) within the glycine/serine-rich domain of ACVR1/ALK2, a bone morphogenetic protein type I receptor. "
09/01/2007 - "Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation in the glycine-serine activation domain of ACVR1, a bone morphogenetic protein type I receptor. "

09/15/2002 - "Multivariate survival analysis with doubly-censored data: application to the assessment of Accutane treatment for fibrodysplasia ossificans progressiva."
01/01/1998 - "Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin."
02/01/1990 - "Failure of surgery and isotretinoin to relieve jaw immobilization in fibrodysplasia ossificans progressiva: report of two cases."
02/01/1990 - "Two patients with fibrodysplasia ossificans progressiva who presented with jaw immobilization due to formation of bone between the maxilla and mandible were treated with surgical resection of their ectopic bone in conjunction with experimental, adjunctive medical therapy using isotretinoin. "
03/01/1988 - "A 9-year-old boy, treated with high-dose isotretinoin therapy for fibrodysplasia ossificans progressiva, developed dense metaphyseal bands and growth arrest. "

11/01/1976 - "Treatment of traumatic myositis ossificans circumscripta; use of aspiration and steroids."
01/01/1998 - "The results suggest the possibility that intravenous administration of ethane-1-hydroxy-1-diphosphonate and oral steroids may be helpful for the treatment of fibrodysplasia ossificans progressiva, but more control data on the spontaneous resolution of early flareups are needed."
06/01/2008 - "Myositis ossificans with pain and insufficient flexion of hip (120 degrees) happened in 1 case and the pain disappeared after non-steroid anti-inflammatory drugs were taken. "
01/01/2012 - "Myositis ossificans can have a septical presentation but therapy is, at first, medical with non steroid anti inflammatory drugs and no antibiotic therapy."

06/01/2021 - "In the pararectus approach group, there was one patient (3.3%) with postoperative wound fat liquefaction, and the wound completely improved by secretion culture, enhanced dressing and effective antibiotics, one patient (3.3%) developed lateral femoral cutaneous nerve injury; One case (3.3%) of postoperative myositis ossificans occurred in the ilioinguinal approach group, and there were no obvious symptoms. "
02/01/2009 - "Complications included pin site infections in one case, treated by oral antibiotics and dressings, and severe degenerative changes with myositis ossificans in one case. "
02/01/2008 - "Except for 2 (6.5%) pin-tract infections, which were resolved by oral antibiotics and pin removal, none of the patients had early or late complications, not even neurological deficit or myositis ossificans. "
01/01/2012 - "Myositis ossificans can have a septical presentation but therapy is, at first, medical with non steroid anti inflammatory drugs and no antibiotic therapy."

03/01/2004 - "Myositis ossificans circumscripta of the knee improved by alendronate."

01/01/2016 - "Correction: High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva."
01/01/2016 - "High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva."
05/06/2015 - "Clinicians should consider myositis ossificans as a possible diagnosis for a soft tissue mass in the hand, thereby avoiding unnecessarily aggressive therapy."
08/12/2010 - "Clinicians should consider myositis ossificans as a possible diagnosis for a soft tissue mass in the limb of an older patient, thereby avoiding unnecessarily aggressive therapy."
10/01/2006 - "Pre- and post-therapy MR imaging in fibrodysplasia ossificans progressiva."

02/01/2014 - "General anesthesia for dental procedures in patients with fibrodysplasia ossificans progressiva: a review of 42 cases in 30 patients."
07/01/2011 - "Extraction of 6 molars under general anesthesia in patient with fibrodysplasia ossificans progressiva."
02/01/1989 - "General anesthesia and fibrodysplasia ossificans progressiva."
02/01/2020 - "Successful Airway and Anesthesia Management Using a High-Flow Nasal Cannula in a Fibrodysplasia Ossificans Progressiva Patient During General Anesthesia: A Case Report."
07/01/2014 - "General anesthesia treatment of propriospinal myoclonus in a patient with fibrodysplasia ossificans progressiva."

01/01/1998 - "The results suggest the possibility that intravenous administration of ethane-1-hydroxy-1-diphosphonate and oral steroids may be helpful for the treatment of fibrodysplasia ossificans progressiva, but more control data on the spontaneous resolution of early flareups are needed."

02/01/2007 - "Taken together, these findings demonstrate that bone marrow transplantation did not cure fibrodysplasia ossificans progressiva in the patient in this study, most likely because the hematopoietic cell population is not the site, or at least not the dominant site, of the intrinsic dysregulation of the BMP signaling pathway in fibrodysplasia ossificans progressiva. "
01/01/1983 - "Successful second bone marrow transplantation in a patient with myositis ossificans progressiva and aplastic anemia."
02/01/2007 - "We identified a patient with fibrodysplasia ossificans progressiva who had undergone bone marrow transplantation for the treatment of intercurrent aplastic anemia twenty-five years earlier and investigated whether the clinical course of the fibrodysplasia ossificans progressiva had been influenced by bone marrow replacement or immunosuppression, or both. "

01/01/2021 - "It is challenging to study heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP) due to the contraindication of invasive techniques (i.e., bone biopsies), which can trigger flare-ups. "
05/01/1987 - "The contraindications to the procedure are fibrous union or ununited trochanteric osteotomy from prior total hip replacement, severe acetabular protrusion of the acetabular component, advanced myositis ossificans, ankylosis of the hip, and advanced proximal femoral osteoporosis. "